New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CAT;IQNT;GRMN;JCP;JNJ;KRC;NKTR;STRA;VRTX;VNO;BMY;PBR;HES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
December 19, 2014
11:08 EDTJNJJohnson & Johnson receives positive CHMP opinion to extend Velcade indication
Subscribe for More Information
09:37 EDTJCPActive equity options trading
Active equity options trading according to Track Data: AAPL TSLA BBRY AMZN CELG GILD JCP AMAT FB
08:56 EDTVNOVornado completes sale of 1740 Broadway for $605M
Subscribe for More Information
06:53 EDTSTRAWhitie House unveils college ratings blueprint, Reuters says
Subscribe for More Information
06:36 EDTCATObama administration to ease many parts of Cuba embargo, NY Times says
Subscribe for More Information
December 18, 2014
16:01 EDTPBROptions Update; December 18, 2014
Subscribe for More Information
11:31 EDTCATCaterpillar sales trends suggest 'muted' 2015 outlook, says Wells Fargo
Wells Fargo says Caterpillar's November retail sales trends were weak with growth trends decelerating from October in all segments. Wells believes weakening demand trends suggest Caterpillar may provide "a muted" outlook for 2015, and the firm stays below consensus with its 2015 expectations. Wells has a Market Perform rating on Caterpillar.
09:47 EDTCATCaterpillar reports retail machines sales down 10% in three months end November
Subscribe for More Information
09:35 EDTPBRActive equity options trading
Active equity options trading according to Track Data: AAPL FB TSLA PBR RAD AMAT NFLX GILD KMI TWTR
December 17, 2014
10:41 EDTPBRStocks with call strike movement; TWTR PBR
Twitter (TWTR) May 41 call option implied volatility decreased 3% to 57, Petrobras (PBR) April 8 call option implied volatility decreased 7% to 65 according to IVolatility.
09:04 EDTJNJHalozyme enters collaboration pact with Janssen for ENHANZE Technology
Subscribe for More Information
09:02 EDTJNJHalozyme enters collaboration pact with Janssen for ENHANZE Technology
Subscribe for More Information
08:06 EDTJNJInovio appoints Zane Yang as VP, Clinical Development, Oncology
Subscribe for More Information
06:22 EDTPBRPetrobras CEO facing pressure to step down amid corruption claims, WSJ reports
Subscribe for More Information
December 16, 2014
12:22 EDTHESAnadarko, BG Group 'widely seen' as targets amid oil slump, FT says
Subscribe for More Information
11:31 EDTPBRStocks with call strike movement; TWTR PBR
Subscribe for More Information
09:59 EDTCAT, HESOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:36 EDTPBRActive equity options trading
Active equity options trading according to Track Data: AAPL AMZN C TSLA PBR TWTR NFLX JPM CLF ABX
08:53 EDTCATCaterpillar downgraded to Underperform from Neutral at Macquarie
Subscribe for More Information
08:47 EDTBMYHemispherx Ampligen provides anti-tumor activity
Subscribe for More Information
08:24 EDTCATCaterpillar downgraded to Underperform from Neutral at Macquarie
07:30 EDTHESHess Corp. downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley downgraded Hess to Equal Weight citing relative outperformance vs. Bakken names and another reduction in oil price forecasts and capex reductions. Price target lowered to $73 from $101.
07:20 EDTJNJGeron announces early HSR clearance for collaboration with Janssen
Subscribe for More Information
December 15, 2014
16:00 EDTPBROptions Update; December 15, 2014
Subscribe for More Information
14:45 EDTPBRPetrobras volatility elevated as shares at low end of ten-year range
Petrobras overall option implied volatility of 71 compares to its 26-week average of 61 according to Track Data, suggesting large near term price movement.
10:44 EDTVNOVornado to complete Urban Edge spin-off by January 2015
Subscribe for More Information
09:38 EDTPBR, JCPActive equity options trading
Subscribe for More Information
09:06 EDTVRTXVertex names David Altshuler as Chief Scientific Officer
Subscribe for More Information
08:56 EDTHESHess Corp. coverage resumed with a Buy at Goldman
Target $92.
08:04 EDTPBRPetrobras coverage assumed with a Neutral at Credit Suisse
December 14, 2014
13:28 EDTPBRPetrobras reports certain Q3 financial results, delays complete report
Subscribe for More Information
December 12, 2014
16:41 EDTKRCKilroy Realty files $300M common stock offering
Subscribe for More Information
16:00 EDTPBROptions Update; December 12, 2014
Subscribe for More Information
14:01 EDTJNJGenOn Energy to receive $3M milestone payment in Janssen collaboration
Genmab announced it has reached a milestone in its DuoBody technology platform collaboration with Janssen Biotech (JNJ), triggering a $3M payment. The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting cancer. Today's news will not impact Genmab's 2014 financial guidance.
10:01 EDTKRCOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:35 EDTHESActive equity options trading
Subscribe for More Information
08:01 EDTVRTXPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
06:09 EDTKRCKilroy Realty initiated with a Neutral at DA Davidson
Subscribe for More Information
December 11, 2014
18:03 EDTNKTRNektar reports data from Phase 3 BEACON study of NKTR-102
Nektar Therapeutics presented biomarker data from a sub-study of the Phase 3 BEACON study of etirinotecan pegol (NKTR-102) which collected and analyzed circulating tumor cell samples from patients in the study. A total of 80% of the 852 patients enrolled in the BEACON trial participated in the CTC sub-study. Among the 627 patients who participated and had evaluable baseline samples, CTCs were detected in 97% of these samples. For the 611 evaluable baseline patient samples which yielded CTCs, potential NKTR-102 target-specific pharmacodynamic biomarkers were detected in the majority of samples. The pharmacodynamic biomarkers assessed in the CTC sub-study were chosen because of their potential ability to predict response to topoisomerase inhibition as well as to measure chemo-sensitivity in metastatic cancer patients
11:32 EDTPBRStocks with call strike movement; GPRO PBR
Subscribe for More Information
09:37 EDTPBRActive equity options trading
Subscribe for More Information
08:05 EDTNKTRFDA Pediatric Oncologic Subcommittee to hold a meeting
Subscribe for More Information
07:45 EDTPBRPetrobras volatility elevated as shares trade near ten-year low
Subscribe for More Information
07:28 EDTHESHess volatility elevated as oil trades near 65-month low
Subscribe for More Information
07:28 EDTVRTXCBI to hold a summit
2nd Specialty Data Optimization Summit is being held in Philadelphia on December 11.
December 10, 2014
16:00 EDTPBROptions Update; December 10, 2014
Subscribe for More Information
06:08 EDTBMYBristol-Myers partners with Ono Pharma and Kyowa Hakko Kirin for oncology trial
Subscribe for More Information
December 9, 2014
16:35 EDTBMYBristol-Myers raises dividend to 37c per share from 36c per share
Subscribe for More Information
08:25 EDTBMYBristol-Myers data positive, says BMO Capital
Subscribe for More Information
08:02 EDTNKTRMoventig approved in EU for opioid-induced constipation
Nektar (NKTR) reported partner AstraZeneca (AZN) announced that MOVENTIG has been granted Marketing Authorisation by the European Commission for the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative. MOVENTIG is the first once-daily oral peripherally-acting mu-opioid receptor antagonist to be approved in the European Union.
07:44 EDTNKTRAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:50 EDTJNJPharmacyclics data demonstrates safety, durability response
New, 27-month IMBRUVICA median follow-up data announced by Pharmacyclics (PCYC) support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma, or MCL, an aggressive type of lymphoma. More than 30% of IMBRUVICA patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Nearly half of the 111 patients treated were still living at the time of the data analysis. A second Phase II trial looked at IMBRUVICA's efficacy and safety as a single-agent treatment for MCL patients who previously had received rituximab combination therapy and at least two cycles of bortezomib. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:43 EDTJNJPharmacyclics reports IMBRUVICA data shows 84% PFS rate at one year
Pharmacyclics (PCYC) announced new, longer term data in IMBRUVICA patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, including high-risk CLL patients with deletion 17p. Results from the Phase III RESONATE trial demonstrated an 84% progression-free survival, or PFS, rate in all patients with previously treated CLL or small lymphocytic lymphoma, or SLL, who received IMBRUVICA and a 94% PFS rate in patients who received only one prior therapy at 12 months. Separately, follow-up data was reported from Phase II RESONATE-17, or PCYC-1117, the largest prospective trial dedicated to studying CLL or SLL patients with del 17p. The data showed that IMBRUVICA was associated with an 83% overall response rate, or ORR, at a median follow up of 11.5 months. At 12 months, the estimated PFS was 79%. These results and additional data were presented here at the 56th American Society of Hematology, or ASH, Annual Meeting, highlighting IMBRUVICA's sustained efficacy in relapsed/refractory patients who have received at least one prior therapy. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:27 EDTJNJPharmacyclics IMBRUVICA Phase II combination data shows positive profile
Subscribe for More Information
December 8, 2014
16:00 EDTPBROptions Update; December 8, 2014
Subscribe for More Information
13:32 EDTBMYPfizer, Bristol-Myers announce results of human study on Eliquis
Bristol-Myers Squibb Company (BMY) and Pfizer (PFE) announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis by 4-factor prothrombin complex concentrates in healthy subjects. The study results demonstrated that both PCCs, Sanquin’s Cofact and CSL Behring’s Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis in several coagulation assessments, including endogenous thrombin potential. The full data will be presented today during the Antithrombotic Therapy: Anticoagulant Therapy session at the 56th annual meeting of the American Society of Hematology in San Francisco, CA. The study was an open label, randomized, placebo-controlled, three-period crossover study in 15 healthy, adult subjects. Within each period, subjects received Eliquis 10 mg twice daily. On day four, three hours after Eliquis administration, subjects received a 30-minute infusion of 4-factor PCCs, either 50 IU/kg Cofact or Beriplex P/N, or an equivalent volume of saline solution. The effect of Cofact and Beriplex P/N on the pharmacodynamics of Eliquis was based upon changes in endogenous thrombin potential, a measure of thrombin-mediated coagulation. Treatment periods were separated by an 11-day washout, after which the alternate treatment was administered. In this study, no serious adverse events, bleeding-related events or signs of thrombosis were reported with Eliquis administration with or without PCC treatment. Overall, these data demonstrate that Cofact and Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis as measured by ETP and support further evaluation of PCCs in the management of patients treated with Eliquis who require reversal of its anticoagulant effect.
11:38 EDTPBRStocks with call strike movement; PBR VXX
Subscribe for More Information
07:29 EDTNKTRUBS to hold investor trip
Subscribe for More Information
07:18 EDTNKTRUBS to hold investor trip
2014 Annual West Coast Investor Trip travels on the West Coast on December 8-10.
05:53 EDTBMYStocks with implied volatility movement; BSX BMY
Subscribe for More Information
December 7, 2014
14:54 EDTJNJIMBRUVICA data suggests promise in multiple myeloma
Subscribe for More Information
14:10 EDTBMYAmerican Society of Hematology to hold a meeting
Subscribe for More Information
13:06 EDTBMYBMY announces positive results in Phase 1b trial evaluating Opdivo
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use